Our Pricing

Is Retatrutide Safe? What UK Clinical Evidence Shows

If you're wondering is retatrutide safe, you're asking the right question before considering any weight loss medication. Retatrutide is an investigational triple-receptor agonist currently undergoing Phase 3 clinical trials, showing promising safety data in published studies but not yet licensed for use in the UK by the MHRA. At Cured Pharmacy, our UK-registered clinical team helps patients understand emerging treatments and access currently licensed alternatives with established safety profiles.

Is Retatrutide Safe? Understanding the Clinical Trial Data

Retatrutide's safety profile has been evaluated in multiple Phase 2 trials involving over 1,000 participants with obesity. The most comprehensive trial, published in the New England Journal of Medicine, tracked participants for 48 weeks and reported that retatrutide was generally well tolerated, with most adverse events classified as mild to moderate [1]. The trial showed that 92% of participants completed the study, suggesting acceptable tolerability across different dose levels.

The safety data from these trials indicates that retatrutide produces side effects consistent with other GLP-1-based medications. Gastrointestinal symptoms — including nausea, diarrhoea, and vomiting — were the most commonly reported adverse events, affecting approximately 60-70% of participants at higher doses [1]. These symptoms typically occurred during dose escalation and diminished over time as patients adapted to treatment.

Serious adverse events were reported in fewer than 5% of trial participants, with no deaths attributed to retatrutide during the Phase 2 studies [1]. However, it's crucial to note that long-term safety data beyond one year remains limited, and the medication has not undergone the full regulatory review required for UK market authorisation.

How Retatrutide Works and Why Safety Matters

Retatrutide is a triple-receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously — a novel mechanism that distinguishes it from currently licensed treatments [2]. This triple action influences appetite regulation, energy expenditure, and metabolic function through multiple pathways, which explains both its efficacy and its side effect profile.

Understanding whether retatrutide is safe requires comparing it to established medications. Tirzepatide, available in the UK as Mounjaro, activates two of the same receptors (GIP and GLP-1) and has completed extensive Phase 3 trials with robust long-term safety data [3]. Clinical trials showed tirzepatide produced average weight reductions of 22.5% over 72 weeks in the SURPASS-3 trial, with a well-characterised safety profile approved by the MHRA [3].

The addition of glucagon receptor activation in retatrutide may theoretically increase metabolic effects, but it also introduces questions about long-term cardiovascular and hepatic safety that require further investigation. Phase 3 trials currently underway will provide more definitive answers about retatrutide's safety profile across diverse patient populations.

Triple vs Dual Receptor Activation

The key safety consideration with retatrutide centres on its triple-receptor mechanism. Glucagon receptor activation increases energy expenditure and fat metabolism, but glucagon also plays a role in raising blood glucose levels [2]. Trial data suggests retatrutide maintains favourable glycaemic control despite glucagon activation, though long-term metabolic effects require ongoing monitoring.

Retatrutide Side Effects: What Clinical Trials Report

When evaluating is retatrutide safe, the side effect profile provides critical insight. Phase 2 trials reported that nausea affected 55-65% of participants at therapeutic doses, typically peaking during the first 4-8 weeks of treatment [1]. Diarrhoea occurred in approximately 35-45% of participants, whilst vomiting affected 20-30% depending on the dose level.

Importantly, discontinuation rates due to adverse events ranged from 8-12% across dose groups — comparable to or slightly higher than rates seen with semaglutide in STEP trials (approximately 7%) [4]. Most participants who discontinued did so within the first 20 weeks of treatment, suggesting that patients who tolerate initial dose escalation generally continue therapy successfully.

Less common but clinically significant adverse events included increases in heart rate (averaging 5-10 beats per minute), gallbladder-related disorders (occurring in approximately 2-3% of participants), and injection site reactions [1]. No cases of medullary thyroid carcinoma or pancreatitis were reported in Phase 2 trials, though these remain theoretical risks requiring long-term surveillance.

Managing Gastrointestinal Side Effects

Trial protocols used gradual dose escalation to minimise gastrointestinal symptoms, starting at 0.5 mg weekly and increasing every 4 weeks [1]. Participants who followed dietary modifications — including smaller, more frequent meals and reduced fat intake — reported better tolerability. These strategies are equally applicable to currently licensed GLP-1 medications available through Cured Pharmacy.

Is Retatrutide Approved in the UK? Regulatory Status

Retatrutide is not currently licensed for use in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). The medication remains in Phase 3 clinical development, with results expected in 2025-2026 before any regulatory submission occurs [2]. UK patients cannot legally access retatrutide outside of approved clinical trials at this time.

The MHRA licensing process requires comprehensive safety data across multiple large-scale trials, typically involving 3,000-5,000 participants followed for at least two years. This rigorous evaluation ensures that any medication approved for UK use has demonstrated acceptable safety and efficacy in diverse patient populations, including those with common comorbidities such as hypertension, dyslipidaemia, and prediabetes.

Until retatrutide completes this regulatory pathway, UK patients seeking evidence-based weight loss treatment can access MHRA-licensed alternatives with established safety profiles. Mounjaro (tirzepatide) offers a dual-receptor mechanism with extensive Phase 3 data, whilst Wegovy (semaglutide) and Saxenda (liraglutide) provide proven GLP-1-based options, all available through Cured Pharmacy following clinical assessment by UK prescribers.

Retatrutide vs Licensed UK Alternatives: Safety Comparison

Comparing whether retatrutide is safe versus established treatments requires examining head-to-head data. Currently, no direct comparison trials exist between retatrutide and tirzepatide or semaglutide. However, cross-trial comparisons suggest similar gastrointestinal side effect profiles, with retatrutide showing slightly higher nausea rates (60-65%) compared to tirzepatide at maximum dose (approximately 55%) [1][3].

Tirzepatide's safety profile has been validated across six Phase 3 SURPASS trials involving over 10,000 participants, with follow-up data extending beyond three years in some cohorts [3]. This extensive evidence base allowed the MHRA to approve Mounjaro for weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, subject to prescriber assessment.

Semaglutide, available as Wegovy, has even longer real-world safety data, with over 500,000 patient-years of exposure globally since its approval for weight management [4]. The STEP trial programme demonstrated cardiovascular safety, with ongoing trials investigating potential cardiovascular benefits. This depth of evidence provides reassurance that currently unavailable with investigational agents like retatrutide.

Making Informed Treatment Decisions

When considering is retatrutide safe for your individual circumstances, consultation with a UK prescriber is essential. At Cured Pharmacy, our clinical team assesses your medical history, current medications, and weight loss goals to recommend appropriate licensed treatments. All prescription medications require online assessment, which takes under three minutes and ensures personalised, safe prescribing aligned with NICE guidance.

Licensed Weight Loss Treatments Available at Cured Pharmacy

While retatrutide undergoes continued clinical development, UK patients can access proven weight loss medications with comprehensive safety data. Mounjaro (tirzepatide) represents the most advanced licensed treatment, offering dual GIP/GLP-1 receptor activation with average weight reductions of 20-22.5% in clinical trials [3]. Starting from £135.00 Mounjaro requires once-weekly subcutaneous injection and is suitable for adults meeting BMI criteria following prescriber assessment.

Wegovy (semaglutide) provides an established GLP-1 receptor agonist option, backed by the extensive STEP trial programme showing average weight loss of 15% over 68 weeks [4]. Available from £135.00 Wegovy offers competitive pricing with the same once-weekly injection schedule. For patients preferring daily injections or requiring a lower-cost option, Saxenda (liraglutide) starts from £135.00 and has been licensed in the UK since 2015.

Cured Pharmacy guarantees the lowest prices in the UK for all weight loss medications, with transparent upfront pricing displayed before your free consultation. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), ensures every prescription is clinically appropriate and safely dispensed. All medications are genuine UK-licensed products delivered in 100% discreet packaging, typically within 24-48 hours of prescriber approval.

Starting Your Weight Loss Journey Safely

Beginning treatment with any weight loss medication requires careful medical assessment. Our online consultation takes under three minutes and covers your medical history, current medications, previous weight loss attempts, and treatment goals. UK prescribers review each assessment individually, ensuring that recommended treatments are safe and appropriate for your specific circumstances. If prescribed, your medication is dispensed by our GPhC-registered pharmacy and delivered discreetly to your chosen address.

Scientific References

1. Jastreboff, A. M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
2. Coskun, T., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247. https://doi.org/10.1016/j.cmet.2022.07.013
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.